Skip to content
Company Analysis

Prestige Consumer Healthcare In PBH

A comprehensive view of key metrics, scores, and financial health for Prestige Consumer Healthcare In

Overview of Prestige Consumer Healthcare Inc.

PBH NYQ
Healthcare Drug Manufacturers - Specialty & Generic Mid Cap
Prestige Consumer Healthcare Inc. (PBH), is a Mid Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $61.45, about 7.5% overvalued vs fair value, -27.6% 1Y return, placing in the top 10% of its sector.
$61.45
-0.73%
As of March 13, 2026
Previous close • Vol 90d: 24.1%
52-Week Range
Market Cap
$3.18B
Enterprise Value
$4.20B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Prestige Consumer Healthcare In.

Top Beats
No strong beats yet

Quick Facts

Website https://www.prestigebrands.com
HQ Tarrytown, NY
Employees 600
Fiscal year Mar 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$52
$57
$62
Current: $61.45 -8% vs base

Engine Room Money Flow™

Mid Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$1.1B
1.1%%
Gross Profit
$634.5M
1.6%%
Operating Income (EBIT)
$331.8M
-3.3%%
Operating Cash Flow
$251.5M
1%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
75.8%
Fair

Moderate cash conversion - some working capital drag

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$55.6M
22.9% of FCF

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
1
Active Leaks
1/1
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Prestige Consumer Healthcare In's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
80
/100
Strong
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
84
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing PBH's balance between Growth (22.2%), Profitability (41.4%), and Safety (36.4%). Growth 22% Safety 36% Profitability 41%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

44th percentile vs peers
45
Key Signals
Rev Growth YoY 1.1% 38p EPS CAGR 3Y 2.0% 62p Revenue CAGR 3Y 1.5% 34p EPS Growth YoY 2.7% 40p TSR 20.3% 68p
Strengths
  • Interest Coverage Ratio in top 20% of peers (6.97, 88th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • Operating Margin in top 20% of peers (30.7%, 94th percentile)
Risks

No significant risks identified for this axis.

Profitability

83th percentile vs peers
83
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

73th percentile vs peers
73
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Prestige Consumer Healthcare In.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$56.84
- - -
-7.5% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info